Phosphatase and tensin homolog (PTEN) was identified as a tumor suppressor that is mutated in a large number of cancers at high frequency. It is one of the most commonly lost tumor suppressors in human cancer. During tumor development, mutations and deletions of PTEN occur that inactivate its enzymatic activity leading to increased cell proliferation and reduced cell death. Frequent genetic inactivation of PTEN occurs in glioblastoma, endometrial cancer, and prostate cancer; and reduced expression is found in many other tumor types such as lung and breast cancer.
Pathway
3-phosphoinositide degradation; Adaptive Immune System; BCR signaling pathway; Constitutive PI3K/AKT Signaling in Cancer
Citations
Publication ()
Have you cited DMAB-DCC095 in a publication? Let us know and earn a reward for your research.
My Review for Anti-PTEN (mutation R130G) Monoclonal Antibody, clone XH103
Creative Diagnostics products are for RESEARCH USE ONLY, please make sure your review is research based.
Required fields are marked with *
Terms and conditions:
We will select high-quality review customers and offer a $30 coupon for your next purchase.
All product reviews must be submitted in the English language.
Creative Diagnostics will not share any personal information of applicants, and all information will be treated with strict confidentiality and will not be sold or disclosed to a third party.
COA
Publication 
Loading ......
